Recombinant Human IL-23 protein (His Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
His Tag
Activity
not tested
Cat no : Eg1304
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human IL-12B Ile23-Ser328 (Accession# P29460)+ linker + IL-23A Arg20-Pro189 (Accession# Q9NPF7) with a His tag at the C-terminus. |
| GeneID | 3593(IL-12B), 51561(IL-23A) |
| Accession | P29460(IL-12B), Q9NPF7(IL-23A) |
| PredictedSize | 58.4 kDa |
| SDS-PAGE | 52-60 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
IL-12 and IL-23 are heterodimeric cytokines with a common p40 subunit (PMID: 11114383). IL-12 is composed of the IL-12 p40 subunit linked to the IL-12 p35 subunit, and the heterodimer signals through the IL-12 receptor (IL-12R), which comprises the IL-12Rβ1 and IL-12Rβ2 subunits. IL-23 is composed of the IL-23 p19 subunit and the IL-12 p40 (IL-12/23p40) subunit, which signals through IL-23R and IL-12Rβ1 (PMID: 11114383; 26121196 ). The importance of IL-23 has been confirmed by clinical data, as monoclonal antibodies (MABs) targeting the p40 subunit (shared by IL-23 and IL-12), as well as p19 (specific for IL-23) were effective in therapy for psoriasis and psoriatic arthritis (PMID: 25754330; 18486740).
References:
1.Oppmann, B. et al.(2000) Immunity. 13(5):715-25. 2.Teng, MW.et al.(2015) Nat Med. 21(7):719-29. 3.Kopp, T. et al.(2015) Nature. 521(7551):222-6. 4.Papp, KA. et al.(2008) Lancet. 371(9625):1675-84.